Literature DB >> 23393363

Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor.

Michela Marcenaro1, Stefano Vagge, Liliana Belgioia, Dario Agnese, Giorgio Lamanna, Elisa Mantero, Marco Gusinu, Stefania Garelli, Francesca Cavagnetto, Stefano Agostinelli, Renzo Corvò.   

Abstract

AIM: To evaluate the feasibility and outcomes of stereotactic body radiotherapy (SBRT) by helical tomotherapy (HT) for patients with primary or secondary lung cancer. PATIENTS AND METHODS: Between March 2009 and January 2012, 56 patients were selected as candidates for the study and were divided into two subgroups. The ablative SBRT group included 27 patients with T1-T2 non-small cell lung cancer who received four to five large-dose fractions in two weeks and the palliative SBRT group included 29 patients with lung metastases treated with eight lower-dose fractions in four weeks.
RESULTS: No differences in acute toxicities were found between different fractionation schemes with different overall treatment times. Actuarial local control at 24 months was better for the ablative group (69.6%) than for the palliative one (40.4%) (p=0.0019).
CONCLUSION: HT-based SBRT was feasible and well-tolerated. Local control was satisfactory for patients treated with ablative SBRT but unsatisfactory for those treated with palliative SBRT. Outcomes also suggest the use of ablative SBRT fractionation for palliative intent.

Entities:  

Mesh:

Year:  2013        PMID: 23393363

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Authors:  S Arcangeli; L Agolli; L Portalone; M R Migliorino; M G Lopergolo; A Monaco; J Dognini; M C Pressello; S Bracci; V Donato
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

Review 2.  The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer.

Authors:  Zhengfei Zhu; Xiaolong Fu
Journal:  Transl Lung Cancer Res       Date:  2015-06

3.  Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis.

Authors:  A Casutt; H Bouchaab; C Beigelman-Aubry; J Bourhis; A Lovis; O Matzinger
Journal:  Br J Radiol       Date:  2015-03-04       Impact factor: 3.039

4.  Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours.

Authors:  Stefano Arcangeli; Lorenzo Falcinelli; Stefano Bracci; Alessandro Greco; Alessia Monaco; Jessica Dognini; Cinzia Chiostrini; Rita Bellavita; Cynthia Aristei; Vittorio Donato
Journal:  Br J Radiol       Date:  2017-03       Impact factor: 3.039

5.  Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience.

Authors:  Vanessa Figlia; Rosario Mazzola; Francesco Cuccia; Filippo Alongi; Gianluca Mortellaro; Daniela Cespuglio; Teresa Cucchiara; Giuseppina Iacoviello; Vito Valenti; Massimo Molino; Francesco Verderame; Domenica Matranga; Antonio Lo Casto; Giuseppe Ferrera
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

6.  Pulmonary function in stereotactic body radiotherapy with helical tomotherapy for primary and metastatic lung lesions.

Authors:  Lorenzo Falcinelli; Monia Mendichi; Sara Chierchini; Maria Valentina Tenti; Rita Bellavita; Simonetta Saldi; Gianluca Ingrosso; Valentina Reggioli; Vittorio Bini; Cynthia Aristei
Journal:  Radiol Med       Date:  2020-05-15       Impact factor: 3.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.